Efzofitimod (ATYR1923)

About aTyr Pharma

aTyr Pharma is translating the biology of tRNA synthetases, essential enzymes with newly discovered extracellular signaling functions, into first-in-class medicines for fibrosis and inflammation. The company's lead asset, efzofitimod, has demonstrated proof-of-concept in pulmonary sarcoidosis and is being advanced in a pivotal Phase 3 trial, with a parallel Phase 2 program in SSc-ILD. Through its subsidiary Pangu BioPharma in Hong Kong, aTyr is also exploring bispecific antibodies targeting Neuropilin-2 (NRP2) in oncology, expanding its platform's therapeutic reach.

About aTyr Pharma

aTyr Pharma is translating the biology of tRNA synthetases, essential enzymes with newly discovered extracellular signaling functions, into first-in-class medicines for fibrosis and inflammation. The company's lead asset, efzofitimod, has demonstrated proof-of-concept in pulmonary sarcoidosis and is being advanced in a pivotal Phase 3 trial, with a parallel Phase 2 program in SSc-ILD. Through its subsidiary Pangu BioPharma in Hong Kong, aTyr is also exploring bispecific antibodies targeting Neuropilin-2 (NRP2) in oncology, expanding its platform's therapeutic reach.

Therapeutic Areas